David A. Siegel Bio Atla, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Bio Atla, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 299,700 shares of BCAB stock, worth $410,589. This represents 0.0% of its overall portfolio holdings.
Number of Shares
299,700
Previous 260,900
14.87%
Holding current value
$410,589
Previous $641,000
60.69%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding BCAB
# of Institutions
88Shares Held
24.8MCall Options Held
140KPut Options Held
4.6K-
Soleus Capital Management, L.P. Greenwich, CT4.07MShares$5.57 Million1.14% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$3.81 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.1MShares$2.88 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.91MShares$2.62 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA1.47MShares$2.02 Million0.62% of portfolio
About BioAtla, Inc.
- Ticker BCAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,304,100
- Market Cap $49.7M
- Description
- BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...